Skye Bioscience Inc (SKYE): The NB2111 molecule has blockbuster pote...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Re: None

Thursday, 10/11/2018 2:37:38 PM

Thursday, October 11, 2018 2:37:38 PM

The NB2111 molecule has blockbuster potential in pain management and anti-addiction markets, I look forward to seeing them continue to advance this drug candidate through their pipeline:

http://www.nemusbioscience.com/investor-relations/investor-news/investor-news-details/2017/Nemus-Bioscience-Announces-Presentation-of-NB2111-Analgesic-and-Anti-Addiction-Data-at-NIH-Sponsored-Cannabinoid-Conference/default.aspx

"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854

Keep Last Read

Next 10 Prev Next

Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:27:39 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2024 04:15:09 AM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/17/2024 08:27:44 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:19:14 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:17:16 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:02:13 PM

InvestorsHub NewsWire

Only $200 per official company press release!